EKSO

Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. It operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. It enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. Additionally, the devices assist people with a variety of upper extremity disabilities and enable industrial employees to perform challenging repetitive tasks for extended periods.

Wall Street analysts forecast EKSO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EKSO is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Ekso Bionics Holdings Inc revenue for the last quarter amounts to 4.23M USD, increased 2.37 % YoY.

Ekso Bionics Holdings Inc. EPS for the last quarter amounts to -0.54 USD, decreased -64.71 % YoY.

Ekso Bionics Holdings Inc (EKSO) has 61 emplpoyees as of January 07 2026.

Today EKSO has the market capitalization of 32.33M USD.